Table.
Demographics of study population
| 6w + 1 PCV10 (n=100) | 6w + 1 PCV13 (n=100) | 14w + 1 PCV10 (n=100) | 14w + 1 PCV13 (n=100) | 2 + 1 PCV10 (n=100) | 2 + 1 PCV13 (n=100) | ||
|---|---|---|---|---|---|---|---|
| Sex | |||||||
| Female | 45 (45%) | 51 (51%) | 52 (52%) | 55 (55%) | 45 (45%) | 42 (42%) | |
| Male | 55 (55%) | 49 (49%) | 48 (48%) | 45 (45%) | 55 (55%) | 58 (58%) | |
| Race | |||||||
| Black African | 100 (100%) | 98 (98%) | 100 (100%) | 99 (99%) | 97 (97%) | 99 (99%) | |
| Mixed | 0 | 2 (2%) | 0 | 1 (1%) | 2 (2%) | 1 (1%) | |
| Birthweight, g | 3262·3 (431·6) | 3238·5 (467·2) | 3232·1 (392·1) | 3203·6 (433·6) | 3308·1 (478·2) | 3177·8 (400·6) | |
| Weight at enrolment, kg | 4·93 (0·76) | 4·92 (0·65) | 4·89 (0·55) | 4·83 (0·58) | 4·95 (0·73) | 4·79 (0·61) | |
| Weight-for-age Z score at enrolment | 0·09 (1·06) | 0·13 (0·95) | 0·12 (0·85) | 0·01 (0·85) | 0·12 (1·08) | 0·11 (0·94) | |
| Age at first PCV dose, weeks | 6·39 (0·42) | 6·36 (0·42) | 14·43 (0·53) | 14·58 (0·65) | 6·42 (0·41) | 6·37 (0·4) | |
| Age at second PCV primary dose, weeks | NA | NA | NA | NA | 15·08 (5·31) | 14·5 (0·63) | |
| Age at booster dose, months | 8·96 (0·15) | 8·98 (0·17) | 9·03 (0·4) | 8·98 (0·09) | 9·02 (0·39) | 9·03 (0·52) | |
| Number sampled before booster vaccine | 76 (76%) | 73 (73%) | 69 (69%) | 69 (69%) | 75 (75%) | 76 (76%) | |
| Number receiving booster dose | 94 (94%) | 94 (94%) | 88 (88%) | 90 (90%) | 94 (94%) | 93 (93%) | |
| Weight-for-age Z score at booster dose* | 0·23 (1·32) | 0·26 (1·21) | −0·02 (1·12) | −0·13 (1·13) | 0·14 (1·41) | −0·07 (1·28) | |
| Number sampled 1 month post-booster dose | 94 (94%) | 93 (93%) | 87 (87%) | 90 (90%) | 94 (94%) | 92 (92%) | |
| Age at post-booster dose sampling, months | 9·93 (0·16) | 9·94 (0·14) | 9·99 (0·42) | 9·95 (0·15) | 9·95 (0·19) | 10 (0·53) | |
Data are n (%) or mean (SD). Infants were randomly assigned to receive one primary dose of PCV10 or PCV13 at age 6 weeks (6w + 1 PCV10 and PCV13 groups) or 14 weeks (14w + 1 PCV10 and PCV13 groups) or two primary doses, one each at ages 6 weeks and 14 weeks (2 + 1 groups). All infants received a booster dose at age 40 weeks. PCV=pneumococcal conjugate vaccine. PCV10=ten-valent PCV. PCV13=13-valent PCV. NA=not applicable.
*
Data not available for all randomly assigned infants.